Annual Drug Patent Expirations for STIVARGA Stivarga is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There are five patents…
The post New patent expiration for Bayer Hlthcare drug STIVARGA appeared fi…
New patent expiration for Bayer Hlthcare drug STIVARGA Read Post »
Annual Drug Patent Expirations for LUPRON+DEPOT Lupron Depot is a drug marketed by Abbvie Endocrine Inc and is included in five NDAs. It is available from one supplier. There are…
The post New patent expiration for Abbvie Endocrine drug LUPRON DEPOT ap…
New patent expiration for Abbvie Endocrine drug LUPRON DEPOT Read Post »
Annual Drug Patent Expirations for PRADAXA Pradaxa is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from four suppliers. There are five patents…
The post New patent expiration for Boehringer Ingelheim drug PRADAXA…
New patent expiration for Boehringer Ingelheim drug PRADAXA Read Post »
Annual Drug Patent Expirations for CAPRELSA Caprelsa is a drug marketed by Genzyme Corp and is included in one NDA. It is available from one supplier. There are three patents…
The post New patent expiration for Genzyme Corp drug CAPRELSA appeared first…
New patent expiration for Genzyme Corp drug CAPRELSA Read Post »
PRADAXA (dabigatran etexilate mesylate) Boehringer ingelheim Patent: 6,087,380 Expiration: Jun 28, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact…
The post Drug Patent …
Drug Patent Expirations for the Week of June 26, 2022 Read Post »
Annual Drug Patent Expirations for JUVISYNC Juvisync is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are four patents protecting this drug and three…
The post New patent expiration for Merck Sharp drug JUVISYNC appeared first …
New patent expiration for Merck Sharp drug JUVISYNC Read Post »
Annual Drug Patent Expirations for PEPAXTO Pepaxto is a drug marketed by Oncopeptides Ab and is included in one NDA. There are five patents protecting this drug. This drug has…
The post New patent expiration for Oncopeptides Ab drug PEPAXTO appeared fi…
New patent expiration for Oncopeptides Ab drug PEPAXTO Read Post »
Annual Drug Patent Expirations for PEPAXTO Pepaxto is a drug marketed by Oncopeptides Ab and is included in one NDA. There are five patents protecting this drug. This drug has…
The post New patent expiration for Oncopeptides Ab drug PEPAXTO appeared fi…
New patent expiration for Oncopeptides Ab drug PEPAXTO Read Post »
Annual Drug Patent Expirations for ELESTRIN Elestrin is a drug marketed by Mylan Speciality Lp and is included in one NDA. It is available from one supplier. There is one…
The post New patent expiration for Mylan Speciality drug ELESTRIN appeared first…
New patent expiration for Mylan Speciality drug ELESTRIN Read Post »
Annual Drug Patent Expirations for GELNIQUE+3%25 Gelnique 3% is a drug marketed by Allergan and is included in one NDA. There is one patent protecting this drug. Drug patent litigation…
The post New patent expiration for Allergan drug GELNIQUE 3% appea…
New patent expiration for Allergan drug GELNIQUE 3% Read Post »